David N Taylor
Affiliation: VaxInnate Corporation
- Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseDavid N Taylor
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
Vaccine 30:5761-9. 2012..HA1 was fused to the C-terminus of flagellin in VAX128A, replaced the D3 domain of flagellin in VAX128B and was fused in both positions in VAX128C...
- Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)David N Taylor
VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
Vaccine 29:4897-902. 2011..We evaluated a novel influenza vaccine consisting of the globular head of the HA1 domain of the A/Solomon Islands/3/2006 (H1N1) influenza virus (VAX125) genetically fused to the TLR5 ligand, flagellin, and produced in Escherichia coli...
- Systemic pharmacokinetics of rifaximin in volunteers with shigellosisDavid N Taylor
Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Antimicrob Agents Chemother 52:1179-81. 2008..Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers...
- Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challengeDavid N Taylor
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Clin Infect Dis 42:1283-8. 2006..This double-blind, placebo-controlled study was conducted to assess the efficacy of the nonabsorbed oral antibiotic rifaximin to prevent shigellosis in volunteers challenged with Shigella flexneri...
- Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigensAndrea J Feller
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Vaccine 29:8487-9. 2011..Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen...
- Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidateRobin McKenzie
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Vaccine 26:3291-6. 2008..Days of fecal shedding of the vaccine strain, but not dose ingested, correlated with stronger immune responses. These results suggest that to be effective an attenuated Shigella vaccine must colonize well...
- Poorly absorbed antibiotics for the treatment of traveler's diarrheaDavid N Taylor
Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
Clin Infect Dis 41:S564-70. 2005..More research is warranted to delineate the effects of poorly absorbed antibiotics in invasive infection and to assess the potential for the development of bacterial resistance...
- Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide aloneHerbert L DuPont
Center for Infectious Diseases, University of Texas School of Public Health, Houston, Texas, USA
Clin Gastroenterol Hepatol 5:451-6. 2007..This study evaluated the efficacy and safety of rifaximin-loperamide in the treatment of travelers' diarrhea...
- Rifaximin treatment of pathogen-negative travelers' diarrheaHerbert L DuPont
Center for Infectious Diseases, Houston School of Public Health, The University of Texas, Houston, TX, USA
J Travel Med 14:16-9. 2007..Antibacterial drugs appear to be effective in shortening the illness of a majority of cases of travelers' diarrhea...
- A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrheaDavid N Taylor
Salix Pharmaceuticals, Inc, Morrisville, North Carolina, USA
Am J Trop Med Hyg 74:1060-6. 2006..35 versus rifaximin). Rifaximin was less effective than ciprofloxacin for invasive intestinal bacterial pathogens. Oral rifaximin is a safe and effective treatment of travelers' diarrhea caused by noninvasive pathogens...
- Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteersDavid E Katz
Department of Enteric Infections, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
Infect Immun 72:923-30. 2004..Infect. Immun. 67:3437-3443, 1999), have demonstrated that SC602 is a substantially attenuated candidate vaccine that can evoke protection against the most severe symptoms of shigellosis in a stringent human challenge model of disease...